Biologics Do Not Increase the Risk of Second Malignancy in Rheumatoid Arthritis Patients
American College of Rheumatology (ACR)Treatment with biologics does not increase the risk of a second malignancy in rheumatoid arthritis patients who have a history of cancer, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting.